Table 1 Review of literature with comparison of previous and present studies of OnabotA-injections in PD
Reference | Sample size | Age [yrs] | Gender | Disease duration [yrs] | Dosage/sites | Injection localisation | Outcome measure | Result | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
Giannantoni et al. [15] | 4 | 72–83 | F (4) | 4–12 | 200 IU/20 | Intradetrusor incl. Trigone | UDI bladder diary Pressure flow QoL | Urinary frequency (day-/nighttime) decreased No urgency/urge incontinence ICIQ/UDI improved PVR increased no side effects | 1/3 months 5 months Telephone interview |
Giannantoni et al. [22] | 8 | 66 ± 3 | F (7) M (1) | N/A | 100 IU/10 | Intradetrusor | UDI bladder diary | Urinary frequency (day-/nighttime) decreased ICIQ/UDI improved PVR increased PVR 250 mL -- > ISC in 2 female patients | 1/3/6 months |
Anderson et al. [14] | 20 | 71.5 | F (8) M (12) | 10.6 | 100 IU/10–20 | Intradetrusor incl. Trigone | UDI bladder diary Pressure flow QoL (KHQ) | Urinary frequency (day-/nighttime) decreased PVR increased AUA Symptom score decreased | 6 months |
Kulaksizoglu et al. [21] | 16 | 67.2 ± 5.1 | F (10) M (6) | 6 | 500 IU/30 Dysport® | Intradetrusor | bladder diary QoL (SEAPI) | Urinary frequency (day-/nighttime) decreased No incontinence in 27 % patients ICIQ VAS scale caregiver PVR increased no side effects | 1 week 3/6/9/12 months |
Present study | 10 | 67.9 ± 5.3 | F (4) M (6) | 9.2 ± 8.2 | 200 IU/20 | Intradetrusor incl. Trigone | UDI bladder diary QoL (ICIQ) | Urinary frequency (day-/nighttime) decreased UDI improved QoL (ICIQ) improved PVR increased no side effects | 4 months |